Jaeggi et al conclude "a standardized approach using dexamethasone and beta-stimulation . . . improved the outcome of isolated fetal complete heart block (CHB)." 1 They used this approach in one 7-year period (90% steroid use; 80% survival) and contrasted it with the preceding 7-year period (19% steroid use; 44% survival). We have grave concerns in accepting that their "standardized approach" was responsible for the improved outcome-other reasons and chance alone cannot be excluded.
Response
We wish to thank Rosenthal et al for their comments regarding our recent article. 1 We do not have a ready explanation for the similarities in outcome between our treated and Guy's Hospital's untreated fetal population with isolated complete atrioventricular block (CAVB) since 1997. From the limited data provided by Rosenthal et al it is unclear whether the 2 study populations are truly comparable. Indeed, if beta-stimulation was used in the setting of fetal heart rates Ͻ55 bpm, only 1 (7%) of 14 cases required such treatment at Guy's Hospital when compared with 8 in 19 (42%; PϽ0.05) continued pregnancies in our study since 1997. Moreover, in spite of a general improvement in prenatal detection of fetal anomalies, Guy's Hospital has seen a 46% decline in fetal CAVB numbers since 1997 (14 cases) when compared with 1990 to 1996 (26 cases). This could be related to incomplete data sampling, an altered referral pattern to this center, or both.
Between 1997 and 2003, the live-birth and 1-year outcome of actively managed isolated CAVB improved at our institutes to 95% respectively, when compared with 80% and 47%, respectively, between 1990 to 1997. 1 If 3 cases with pregnancy termination were included, the 1-year survival still improved from 44% to 86%, and not 80% as stated by Rosenthal et al. We believe but cannot be sure that this decreased morbidity and mortality was the result of the change in overall treatment rather than any single intervention or therapy or coincidence. We agree that there are potential risks involved with the use of dexamethasone during pregnancy and that prophylactic therapy is not indicated for anti-Ro/La antibody-associated pregnancies. The value of a transplacental treatment that is reserved for compromised fetuses is unknown apart from a handful of anecdotal case reports. 2 We therefore believe that the efficacy and safety of our and alternative treatment approaches should be further addressed prospectively in a large-scale randomized study.
